First-in-class inhibitors against respiratory viral infections.
to develop new antiviral therapies against different respiratory viral infections. Founded in 2015, ATRIVAattracted sea- soned experts in virology and drug development to form a unique venture targeting the fast and successful validation of a novel approach to fight infectious diseases Inhibitors of certain cellular signaling pathways, the so called “MEK-Inhibitors”, have shown a superior antiviral activity by blocking veplication. This creates an unprecedented potential for truly efficacious and safe the- rapeutics against numerous viral infections. ATRIVA closed a seed financing of € 3 Mn in late 2016. The proceeds of this allows the comoreach clinical development with its lead project ATR-002 for influenza in high-risk patients. We invite you to explore our approach and pipeline presented on this website and encourage you to contact us directly.